NDC 70700-169

Irinotecan hydrochloide

Irinotecan Hydrochloide

Irinotecan hydrochloide is a Intravenous Injection in the Human Prescription Drug category. It is labeled and distributed by Xiromed Llc. The primary component is Irinotecan Hydrochloride.

Product ID70700-169_54edb26e-5716-7c16-d55c-f02e78162346
NDC70700-169
Product TypeHuman Prescription Drug
Proprietary NameIrinotecan hydrochloide
Generic NameIrinotecan Hydrochloide
Dosage FormInjection
Route of AdministrationINTRAVENOUS
Marketing Start Date2019-11-18
Marketing CategoryANDA / ANDA
Application NumberANDA212993
Labeler NameXiromed LLC
Substance NameIRINOTECAN HYDROCHLORIDE
Active Ingredient Strength20 mg/mL
Pharm ClassesTopoisomerase Inhibitor [EPC], Topoisomerase Inhibitors [MoA]
NDC Exclude FlagN
Listing Certified Through2023-12-31

Packaging

NDC 70700-169-22

1 VIAL, SINGLE-DOSE in 1 CARTON (70700-169-22) > 2 mL in 1 VIAL, SINGLE-DOSE
Marketing Start Date2019-11-18
NDC Exclude FlagN
Sample Package?N

NDC SPL Data Element Entries

NDC 70700-169-22 [70700016922]

Irinotecan hydrochloide INJECTION
Marketing CategoryANDA
Application NumberANDA212993
Product TypeHUMAN PRESCRIPTION DRUG
Marketing Start Date2019-11-18

Drug Details

NDC Crossover Matching brand name "Irinotecan hydrochloide" or generic name "Irinotecan Hydrochloide"

NDCBrand NameGeneric Name
68001-480Irinotecan hydrochloideIrinotecan hydrochloide
68083-381Irinotecan hydrochloideIrinotecan hydrochloide
70700-169Irinotecan hydrochloideIrinotecan hydrochloide
© 2025 FDA.report
This site is not affiliated with or endorsed by the FDA.